Business
Sofwave Medical Reports First Quarter Fiscal 2025 Financial Results and Business Highlights
— First quarter revenue of $16.7M, +26% year-over-year growth; IFRS gross margin of 76.3%— First quarter pulse recurring revenue of $7.0M, +49% year-over-year growth— IFRS and non-IFRS operating loss of -$1M and -$0.2M, respectively SAN CLEMENTE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, reported financial results for the first quarter of fiscal year 2025, for
About this update from Sofwave Medical Ltd.
[{"type":"image","alt":"SofWave Medical, Ltd.","displaySize":"","headline":null,"caption":"SofWave Medical, Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":98,"url":"https://media.zenfs.com/en/globenewswire.com/b4145e23394e0750e8b338ae3bd17b14"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/p.oYqpXrsE4DEiyGzsuJTQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b4145e23394e0750e8b338ae3bd17b14","width":300,"height":98}},"lazy":false},{"type":"text","content":"— First quarter revenue of $16.7M, +26% year-over-year growth; IFRS gross margin of 76.3%— First quarter pulse recurring revenue of $7.0M, +49% year-over-year growth— IFRS and non-IFRS operating loss of -$1M and -$0.2M, respectively","length":244,"tagName":"p"},{"type":"text","content":"SAN CLEMENTE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, reported financial results for the first quarter of fiscal year 2025, for the period ended March 31, 2025, and recent business highlights.","length":331,"tagName":"p"},{"type":"text","content":"First Quarter Fiscal 2025 Financial Highlights ","length":46,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"First Quarter Revenue of $16.7M; representing 26% year-over-year growth","length":71,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Recurring Revenue of $7M, a year-over- year increase of 49% growth, representing 42% of total revenue","length":101,"tagName":"p"}]},{"val":[{"type":"text","content":"Gross Profit was $12.7M, a year-over-year increase of 28%","length":57,"tagName":"p"}]},{"val":[{"type":"text","content":"IFRS Gross Margin: 76.3%; *Non-IFRS 76.4%","length":41,"tagName":"p"}]},{"val":[{"type":"text","content":"IFRS Operating Loss: $1.0M, flat as compared to $1.0M in the first quarter of 2024; *Non-IFRS Operating Loss: $0.2M","length":115,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":314,"olType":false}]},{"val":[{"type":"text","content":"Cash and Cash Equivalents as of March 31, 2025: $20.4M, Cash used in the first quarter of 2025 was $1.2M, including a onetime payment of $0.9M related to a trademark litigation, vs. $1.3M used in Q1/24.","length":202,"...